Industrial Biotechnology Post-Graduation Program, University of Tiradentes, Aracaju, Sergipe, Brazil.
Pharmaceutical Sciences Post-Graduation Program, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil.
Appl Microbiol Biotechnol. 2021 Nov;105(21-22):8227-8240. doi: 10.1007/s00253-021-11610-6. Epub 2021 Oct 9.
Leishmania is a complex disease caused by the protozoan parasites and transmitted by female phlebotomine sandfly. The disease affects some of the poorest people on earth with an estimated 700,000 to 1 million new cases annually. The current treatment for leishmaniasis is toxic, long, and limited, in view of the high resistance rate presented by the parasite, necessitating new perspectives for treatment. The discovery of new compounds with different targets can be a hope to make the treatment more efficient. Microbial metabolites and their structural analogues with enormous scaffold diversity and structural complexity have historically played a key role in drug discovery. We found thirty-nine research articles published between 1999 and 2021 in the scientific database (PubMed, Science Direct) describing microbes and their metabolites with activity against leishmanial parasites which is the focus of this review. KEY POINTS: • Leishmania affects the poorest regions of the globe • Current treatments for leishmaniasis are toxic and of limited efficacy • Microbial metabolites are potential sources of antileishmania drugs.
利什曼病是一种由原生动物寄生虫引起的复杂疾病，通过雌性白蛉传播。这种疾病影响着地球上一些最贫穷的人，估计每年有 70 万至 100 万例新病例。鉴于寄生虫的高耐药率，目前对利什曼病的治疗是有毒的、漫长的且有限的，因此需要新的治疗方法。发现具有不同靶点的新化合物可能是提高治疗效果的希望。微生物代谢产物及其具有巨大支架多样性和结构复杂性的结构类似物在药物发现中一直发挥着关键作用。我们在科学数据库（PubMed、Science Direct）中发现了 39 篇发表于 1999 年至 2021 年的研究文章，这些文章描述了具有抗利什曼原虫寄生虫活性的微生物及其代谢产物，这是本次综述的重点。要点： • 利什曼病影响着全球最贫困的地区 • 目前治疗利什曼病的方法有毒性且疗效有限 • 微生物代谢产物是抗利什曼病药物的潜在来源。
